{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:33:56Z","timestamp":1791023636802,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1038\/ncpendmet0941","type":"journal-article","created":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T09:29:04Z","timestamp":1219224544000},"page":"514-523","source":"Crossref","is-referenced-by-count":29,"title":["Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis"],"prefix":"10.1038","volume":"4","author":[{"given":"Socrates","family":"Papapoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpendmet0941_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4: 368\u2013381","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.berh.2005.07.004","volume":"19","author":"ML Bouxsein","year":"2005","unstructured":"Bouxsein ML (2005) Determinants of skeletal fragility. Best Pract Res Clin Rheumatol 19: 897\u2013911","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"BFncpendmet0941_CR3","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E and Delmas PD (2006) Bone quality\u2014the material and structural basis of bone strength and fragility. N Engl J Med 354: 2250\u20132261","journal-title":"N Engl J Med"},{"key":"BFncpendmet0941_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinthera.2004.12.020","volume":"27","author":"D Felsenberg","year":"2005","unstructured":"Felsenberg D and Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27: 1\u201311","journal-title":"Clin Ther"},{"key":"BFncpendmet0941_CR5","first-page":"115","volume":"21","author":"SC Manolagas","year":"2000","unstructured":"Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115\u2013137","journal-title":"Endocr Rev"},{"key":"BFncpendmet0941_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/B978-012470862-4\/50016-7","volume-title":"Osteoporosis","author":"AM Parfitt","year":"2001","unstructured":"Parfitt AM (2001) Skeletal heterogeneity and the purpose of bone remodeling; implications for the understandimg of osteoporosis. In Osteoporosis, 433\u2013447 ( Eds Marcus R  et al.) San Diego: Academic Press"},{"key":"BFncpendmet0941_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00198-005-2035-9","volume":"17","author":"S Viguet-Carrin","year":"2006","unstructured":"Viguet-Carrin S  et al. (2006) The role of collagen in bone strength. Osteoporos Int 17: 319\u2013336","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR8","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1359\/JBMR.040710","volume":"19","author":"R Recker","year":"2004","unstructured":"Recker R  et al. (2004) Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19: 1628\u20131633","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0002-9343(82)90810-5","volume":"72","author":"MP Whyte","year":"1982","unstructured":"Whyte MP  et al. (1982) Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med 72: 193\u2013202","journal-title":"Am J Med"},{"key":"BFncpendmet0941_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF01880415","volume":"1","author":"ME Arlot","year":"1990","unstructured":"Arlot ME  et al. (1990) Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: comparison with normal postmenopausal women. Osteoporos Int 1: 41\u201349","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jbmr.5650050402","volume":"5","author":"EF Eriksen","year":"1990","unstructured":"Eriksen EF  et al. (1990) Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 5: 311\u2013319","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG  et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189\u20131199","journal-title":"N Engl J Med"},{"key":"BFncpendmet0941_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S8756-3282(00)00301-X","volume":"27","author":"PD Delmas","year":"2000","unstructured":"Delmas PD (2000) How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27: 1\u20133","journal-title":"Bone"},{"key":"BFncpendmet0941_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC  et al. (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87: 1586\u20131592","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0941_CR15","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC  et al. (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19: 1250\u20131258","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R  et al. (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 1051\u20131056","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1359\/JBMR.0301243","volume":"19","author":"S Sarkar","year":"2004","unstructured":"Sarkar S  et al. (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19: 394\u2013401","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s001980170020","volume":"12","author":"NH Bjarnason","year":"2001","unstructured":"Bjarnason NH  et al. (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12: 922\u2013930","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","volume":"27","author":"GY Boivin","year":"2000","unstructured":"Boivin GY  et al. (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687\u2013694","journal-title":"Bone"},{"key":"BFncpendmet0941_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","volume":"29","author":"P Roschger","year":"2001","unstructured":"Roschger P  et al. (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29: 185\u2013191","journal-title":"Bone"},{"key":"BFncpendmet0941_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","volume":"39","author":"B Borah","year":"2006","unstructured":"Borah B  et al. (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39: 345\u2013352","journal-title":"Bone"},{"issue":"Suppl 1","key":"BFncpendmet0941_CR22","first-page":"S129","volume":"22","author":"P Roschger","year":"2007","unstructured":"Roschger P  et al. (2007) Mineralization status of bone matrix in postmenopausal women during a 10-year alendronate treatment period. J Bone Miner Res 22 (Suppl 1): S129","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1185\/030079904X20259","volume":"21","author":"R Recker","year":"2005","unstructured":"Recker R  et al. (2005) Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21: 185\u2013194","journal-title":"Curr Med Res Opin"},{"key":"BFncpendmet0941_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","volume":"34","author":"B Borah","year":"2004","unstructured":"Borah B  et al. (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34: 736\u2013746","journal-title":"Bone"},{"key":"BFncpendmet0941_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","volume":"39","author":"LI Plotkin","year":"2006","unstructured":"Plotkin LI  et al. (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs. Bone 39: 443\u2013452","journal-title":"Bone"},{"key":"BFncpendmet0941_CR26","volume-title":"Cochrane Database of Systematic Reviews","author":"GA Wells","year":"2008","unstructured":"Wells GA  et al. (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001155. [10.1002\/14651858.CD001155.pub2]"},{"key":"BFncpendmet0941_CR27","volume-title":"Cochrane Database of Systematic Reviews","author":"G Wells","year":"2008","unstructured":"Wells G  et al. (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD004523. [10.1002\/14651858.CD004523.pub3]"},{"key":"BFncpendmet0941_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1359\/JBMR.050903","volume":"21","author":"ND Nguyen","year":"2006","unstructured":"Nguyen ND  et al. (2006) Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21: 340\u2013349","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR29","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM  et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809\u20131822","journal-title":"N Engl J Med"},{"key":"BFncpendmet0941_CR30","unstructured":"Cranney A  et al. Ibandronate for the prevention of non-vertebral fractures: a pooled analysis of individual patient data. Osteoporos Int, in press"},{"key":"BFncpendmet0941_CR31","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","volume":"165","author":"MR McClung","year":"2005","unstructured":"McClung MR  et al. (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762\u20131768","journal-title":"Arch Intern Med"},{"key":"BFncpendmet0941_CR32","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1210\/jc.2005-1712","volume":"91","author":"DC Bauer","year":"2006","unstructured":"Bauer DC  et al. (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91: 1370\u20131375","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0941_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","volume":"40","author":"JE Compston","year":"2007","unstructured":"Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40: 1447\u20131452","journal-title":"Bone"},{"key":"BFncpendmet0941_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/8756-3282(93)90190-L","volume":"14","author":"AB Hodsman","year":"1993","unstructured":"Hodsman AB and Steer BM (1993) Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14: 523\u2013527","journal-title":"Bone"},{"key":"BFncpendmet0941_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1359\/JBMR.051109","volume":"21","author":"R Lindsay","year":"2006","unstructured":"Lindsay R  et al. (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21: 366\u2013373","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1359\/jbmr.070104","volume":"22","author":"R Lindsay","year":"2007","unstructured":"Lindsay R  et al. (2007) Effects of a one-month treatment with PTH1\u201334 on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22: 495\u2013502","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR37","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1359\/JBMR.050309","volume":"20","author":"M Arlot","year":"2005","unstructured":"Arlot M  et al. (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20: 1244\u20131253","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR38","first-page":"356","volume":"5","author":"J Fox","year":"2005","unstructured":"Fox J  et al. (2005) Treatment of postmenopausal osteoporotic women with parathyroid hormone 1\u201384 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5: 356\u2013357","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"BFncpendmet0941_CR39","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"DW Dempster","year":"2001","unstructured":"Dempster DW  et al. (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16: 1846\u20131853","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR40","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y  et al. (2003) Recombinant human parathyroid hormone1\u201334 [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18: 1932\u20131941","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR41","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1210\/jc.2002-021988","volume":"88","author":"BM Misof","year":"2003","unstructured":"Misof BM  et al. (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88: 1150\u20131156","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0941_CR42","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1210\/jc.2004-2489","volume":"90","author":"EP Paschalis","year":"2005","unstructured":"Paschalis EP  et al. (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 90: 4644\u20134649","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0941_CR43","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM  et al. (2001) Effect of parathyroid hormone1\u201334 on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434\u20131441","journal-title":"N Engl J Med"},{"key":"BFncpendmet0941_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL  et al. (2007) Effect of recombinant human parathyroid hormone1\u201384 on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146: 326\u2013339","journal-title":"Ann Intern Med"},{"key":"BFncpendmet0941_CR45","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","volume":"286","author":"ES Siris","year":"2001","unstructured":"Siris ES  et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286: 2815\u20132822","journal-title":"JAMA"},{"key":"BFncpendmet0941_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SC Schuit","year":"2004","unstructured":"Schuit SC  et al. (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34: 195\u2013202","journal-title":"Bone"},{"key":"BFncpendmet0941_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s001980200069","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA  et al. (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13: 527\u2013536","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/bmj.315.7102.221","volume":"315","author":"CE de Laet","year":"1997","unstructured":"de Laet CE  et al. (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315: 221\u2013225","journal-title":"BMJ"},{"key":"BFncpendmet0941_CR49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA  et al. (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35: 1029\u20131037","journal-title":"Bone"},{"key":"BFncpendmet0941_CR50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA  et al. (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35: 375\u2013382","journal-title":"Bone"},{"key":"BFncpendmet0941_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA  et al. (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16: 155\u2013162","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR52","volume-title":"Assessment of osteoporosis at the primary health-care level. Technical Report","author":"JA Kanis","year":"2007","unstructured":"Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. Sheffield: WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield"},{"key":"BFncpendmet0941_CR53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA  et al. (2008) FRAX\u2122 and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385\u2013397","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR54","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","volume":"11","author":"P Garnero","year":"1996","unstructured":"Garnero P  et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11: 1531\u20131538","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR55","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/bmj.312.7029.482","volume":"312","author":"PL Van Daele","year":"1996","unstructured":"Van Daele PL  et al. (1996) Case\u2013control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 312: 482\u2013483","journal-title":"BMJ"},{"key":"BFncpendmet0941_CR56","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1172\/JCI113725","volume":"82","author":"R Civitelli","year":"1988","unstructured":"Civitelli R  et al. (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82: 1268\u20131274","journal-title":"J Clin Invest"},{"key":"BFncpendmet0941_CR57","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1359\/jbmr.1997.12.4.624","volume":"12","author":"S Gonnelli","year":"1997","unstructured":"Gonnelli S  et al. (1997) The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 12: 624\u2013631","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s002239900713","volume":"65","author":"S Gonnelli","year":"1999","unstructured":"Gonnelli S  et al. (1999) Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65: 359\u2013364","journal-title":"Calcif Tissue Int"},{"key":"BFncpendmet0941_CR59","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1359\/JBMR.0301231","volume":"19","author":"MJ Seibel","year":"2004","unstructured":"Seibel MJ  et al. (2004) Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19: 323\u2013329","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR60","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1359\/JBMR.051018","volume":"21","author":"DC Bauer","year":"2006","unstructured":"Bauer DC  et al. (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21: 292\u2013299","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR61","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1359\/JBMR.050105","volume":"20","author":"P Chen","year":"2005","unstructured":"Chen P  et al. (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20: 962\u2013970","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","volume":"39","author":"PD Delmas","year":"2006","unstructured":"Delmas PD  et al. (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39: 237\u2013243","journal-title":"Bone"},{"key":"BFncpendmet0941_CR63","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM  et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207\u20131215","journal-title":"N Engl J Med"},{"key":"BFncpendmet0941_CR64","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS  et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216\u20131226","journal-title":"N Engl J Med"},{"key":"BFncpendmet0941_CR65","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1359\/JBMR.050714","volume":"20","author":"C Deal","year":"2005","unstructured":"Deal C  et al. (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20: 1905\u20131911","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR66","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B  et al. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745\u2013751","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"BFncpendmet0941_CR67","first-page":"s30","volume":"80","author":"E McCloskey","year":"2007","unstructured":"McCloskey E  et al. (2007) Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis: final results from the EUROFORS trial. Calcif Tissue Int 80 (Suppl 1): s30","journal-title":"Calcif Tissue Int"},{"key":"BFncpendmet0941_CR68","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","volume":"13","author":"F Cosman","year":"1998","unstructured":"Cosman F  et al. (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13: 1051\u20131055","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"BFncpendmet0941_CR69","first-page":"s137","volume":"80","author":"CB Obermaier-Pietsch","year":"2007","unstructured":"Obermaier-Pietsch CB  et al. (2007) Effects of prior antiresorptive therapy on markers of bone formation after 6 months of teriparatide treatment in postmenopausal women with osteoporosis: results from the Eurofors trial. Calcif Tissue Int 80 (Suppl 1): s137","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 1","key":"BFncpendmet0941_CR70","first-page":"S27","volume":"22","author":"P Delmas","year":"2007","unstructured":"Delmas P  et al. (2007) Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: the OPTAMISE study. J Bone Miner Res 22 (Suppl 1): S27","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0941_CR71","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM  et al. (2005) One year of alendronate after one year of parathyroid hormone1\u201384 for osteoporosis. N Engl J Med 353: 555\u2013565","journal-title":"N Engl J Med"},{"key":"BFncpendmet0941_CR72","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS  et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85: 2129\u20132134","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0941_CR73","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","volume":"15","author":"ES Kurland","year":"2004","unstructured":"Kurland ES  et al. (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone1\u201334]. Osteoporos Int 15: 992\u2013997","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR74","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R  et al. (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164: 2024\u20132030","journal-title":"Arch Intern Med"},{"key":"BFncpendmet0941_CR75","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM  et al. (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16: 510\u2013516","journal-title":"Osteoporos Int"},{"key":"BFncpendmet0941_CR76","first-page":"1209","volume-title":"Osteoporosis","author":"SE Papapoulos","year":"1996","unstructured":"Papapoulos SE (1996) Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In Osteoporosis, 1209\u20131233 ( Eds Marcus R  et al.) New York, NY: Academic Press"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0941.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0941","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0941.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:57:06Z","timestamp":1684439826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["BFncpendmet0941"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0941","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}